Sjoukje F Oosting

7PUBLICATIONS
47CO-AUTHORS
Molecular targetsRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 10, 2026
Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment.

|Aug 21, 2026
Impact of Proton versus Photon (Chemo)radiation on Circulating Immune Cells in Head and Neck Cancer.

|Jun 17, 2026
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

|Sep 10, 2025
Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome.

S Hone Lopez, S Loipfinger, A Bhattacharya

|Nov 17, 2022
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.

Sarah R Verhoeff, Sjoukje F Oosting, Sjoerd G Elias

|Sep 14, 2020
Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy.

Johannes Stelwagen, Sjoukje Lubberts, Lars C Steggink

Pageof 2

Frequent Collaborators

2 joint publications

Mathilde Jalving

2 joint publications

Marco de Bruyn

2 joint publications

Elisabeth G E de Vries

2 joint publications

Adrienne H Brouwers